• 1
    LeRoy EC. Systemic sclerosis (scleroderma). In: WyngaardenJB, SmithLH, BennettJC, editors. Cecil text book of medicine. 19th ed. Philadelphia: W. B. Saunders; 1992. p. 15301535.
  • 2
    Kulozik M, Hogg A, Lankat-Buttgereit B, Krieg T. Co-localization of transforming growth factor beta 2 with alpha 1(I) procollagen mRNA in tissue sections of patients with systemic sclerosis. J Clin Invest 1990; 86: 917922.
  • 3
    Jelaska A, Arakawa M, Broketa G, Korn JH. Heterogeneity of collagen synthesis in normal and systemic sclerosis skin fibroblasts: increased proportion of high collagen–producing cells in systemic sclerosis fibroblasts. Arthritis Rheum 1996; 39: 13381346.
  • 4
    LeRoy EC. Increased collagen synthesis by SSc skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 880889.
  • 5
    Buckingham RB, Prince RK, Rodnan GP, Taylor F. Increased collagen accumulation in dermal fibroblast cultures from patients with progressive systemic sclerosis (scleroderma). J Lab Clin Med 1978; 92: 521.
  • 6
    Peltonen J, Kähäri L, Uitto J, Jimenez SA. Increased expression of type VI collagen genes in systemic sclerosis. Arthritis Rheum 1990; 33: 18291835.
  • 7
    Xu WD, LeRoy EC, Smith EA. Fibronectin release by systemic sclerosis and normal dermal fibroblasts in response to TGF-beta. J Rheumatol 1991; 18: 241246.
  • 8
    Rudnicka L, Varga J, Christiano AM, Iozzo RV, Jimenez SA, Uitto J. Elevated expression of type VII collagen in the skin of patients with systemic sclerosis: regulation by transforming growth factor-beta. J Clin Invest 1994; 93: 17091715.
  • 9
    Falanga V, Tiegs SL, Alstadt SP, Roberts AB, Sporn MB. Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis. J Invest Dermatol 1987; 89: 100104.
  • 10
    Ihn H, Tamaki K. Increased phosphorylation of transcription factor Sp1 in scleroderma fibroblasts: association with increased expression of the type I collagen gene. Arthritis Rheum 2000; 43: 22402247.
  • 11
    LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM. A strategy for determining the pathogenesis of systemic sclerosis: is transforming growth factor β the answer? Arthritis Rheum 1989; 32: 817825.
  • 12
    Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-beta receptors by scleroderma fibroblasts: evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 1998; 110: 4751.
  • 13
    Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors. Arthritis Rheum 2001; 44: 474480.
  • 14
    Bloom BB, Humphries DE, Kuang PP, Fine A, Goldstein RH. Structure and expression of the promoter for the R4/ALK5 human type I transforming growth factor-beta receptor: regulation by TGF-beta. Biochim Biophys Acta 1996; 1312: 243248.
  • 15
    Bae HW, Geiser AG, Kim DH, Chung MT, Burmester JK, Sporn MB, et al. Characterization of the promoter region of the human transforming growth factor-beta type II receptor gene. J Biol Chem 1995; 270: 2946029468.
  • 16
    Czuwara-Ladykowska J, Gore EA, Shegogue DA, Smith EA, Trojanowska M. Differential regulation of transforming growth factor-b receptors type I and II by platelet-derived growth factor in human dermal fibroblasts. Br J Dermatol 2001; 145: 569575.
  • 17
    Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum 2001; 44: 731734.
  • 18
    Li G, Li RK, Mickle DA, Weisel RD, Merante F, Ball WT, et al. Elevated insulin-like growth factor-I and transforming growth factor-beta 1 and their receptors in patients with idiopathic hypertrophic obstructive cardiomyopathy: a possible mechanism. Circulation 1998; 98: 144149.
  • 19
    Roulot D, Sevcsik AM, Coste T, Strosberg AD, Marullo S. Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats. Hepatology 1999; 29: 17301738.
  • 20
    Kanzaki T, Shiina R, Saito Y, Zardi L, Morisaki N. Transforming growth factor-beta receptor and fibronectin expressions in aortic smooth muscle cells in diabetic rats. Diabetologia 1997; 40: 383391.
  • 21
    Kim SJ, Im YH, Markowitz SD, Bang YJ. Molecular mechanisms of inactivation of TGF-beta receptors during carcinogenesis. Cytokine Growth Factor Rev 2000; 11: 159168.
  • 22
    Tourkina E, Hoffman S, Fenton JW II, Lipsitz S, Silver RM, Ludwicka-Bradley A. Depletion of protein kinase Cε in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression. Arthritis Rheum 2001; 44: 13701381.
  • 23
    Jimenez SA, Gaidarova S, Saitta B, Sandorfi N, Herrich D, Rosenbloom JC, et al. Role of protein kinase C-d in the regulation of collagen gene expression in scleroderma fibroblasts. J Clin Invest 2001; 108: 13951403.
  • 24
    Needleman BW, Choi J, Burrows-Mezu A, Fontana JA. Secretion and binding of transforming growth factor β by scleroderma and normal dermal fibroblasts. Arthritis Rheum 1990; 33: 650656.
  • 25
    Feng XH, Derynck R. Ligand-independent activation of transforming growth factor (TGF) beta signaling pathways by heteromeric cytoplasmic domains of TGF-beta receptors. J Biol Chem 1996; 271: 1312313129.
  • 26
    Lillien L. Changes in retinal cell fate induced by overexpression of EGF receptor. Nature 1995; 377: 158162.